Characteristics | Lurasidone (NÂ =Â 439) |
---|---|
Age (years), mean (SD) | 42.2 (13.5) |
Female, N (%) | 306 (69.7%) |
Follow-up duration (days), mean (SD) | 225.1 (124.6) |
Diagnosis of schizophrenia or bipolar disorder, N (%) | |
 Schizophrenia spectrum diagnosis | 83 (18.9%) |
 Bipolar disorder diagnosis | 206 (46.9%) |
 Other/unknown diagnosisa | 150 (34.2%) |
Prior use of any second-generation antipsychotics N (%) | 201 (45.8%) |
Prior use of second-generation antipsychotics associated with medium or higher risk for weight gainb | 119 (27.1%) |
Prior use of any first-generation antipsychotic, N (%) | 62 (14.1%) |
Prior use of other medications, N (%) | |
 Antidepressants | 246 (56.0%) |
 Diuretics | 90 (20.5%) |
Comorbidities, N (%) | |
 Depression | 196 (44.6%) |
 Substance abuse | 166 (37.8%) |
 Hypertension | 158 (36.0%) |
 Hyperlipidemia | 155 (35.3%) |
 Diabetes | 89 (20.3%) |
 Chronic obstructive pulmonary disease | 85 (19.4%) |
Charlson Comorbidity Index Score, mean (SD) | 0.8 (1.3) |
Weightc and BMI classificationd | |
 Weight (kg), mean (SD) | 93.9 (25.4) |
 Underweight, N (%) | 4 (0.9%) |
 Normal, N (%) | 70 (15.9%) |
 Overweight, N (%) | 89 (20.3%) |
 Obese, N (%) | 276 (62.9%) |